Ablation of Refractory Ventricular Tachycardia Using Intramyocardial Needle Delivered Heated Saline-Enhanced Radiofrequency Energy: A First-in-Man Feasibility Trial

Author:

Packer Douglas L.1ORCID,Wilber David J.2ORCID,Kapa Suraj1ORCID,Dyrda Katia3ORCID,Nault Isabelle4ORCID,Killu Ammar M.1ORCID,Kanagasundram Arvindh5ORCID,Richardson Travis5ORCID,Stevenson William5ORCID,Verma Atul6ORCID,Curley Michael7ORCID,

Affiliation:

1. Mayo Clinic, Rochester, MN (D.L.P., S.K., A.M.K.).

2. Loyola Univ Medical Center, IL, Maywood (D.J.W.).

3. Montreal Heart Institute, QC (K.D.).

4. Canada Quebec Heart and Lung Institute, Quebec City, Canada (I.N.).

5. Vanderbilt University Medical Center, Nashville, TN (A.K., T.R., W.S.).

6. Southlake Regional Health Centre, Newmarket Ontario, Canada (A.V.).

7. Thermedical, Inc, Waltham, MA (M.C.).

Abstract

Background: Ablation of ventricular tachycardia (VT) is limited by the inability to create penetrating lesions to reach intramyocardial origins. Intramural needle ablation using in-catheter, heated saline-enhanced radio frequency (SERF) energy uses convective heating to increase heat transfer and produce deeper, controllable lesions at intramural targets. This first-in-human trial was designed to evaluate the safety and efficacy of SERF needle ablation in patients with refractory VT. Methods: Thirty-two subjects from 6 centers underwent needle electrode ablation. Each had recurrent drug-refractory monomorphic VT after implantable cardioverter defibrillator implantation and prior standard ablation. During the SERF study procedure, one or more VTs were induced and mapped. The SERF needle catheter was used to create intramural lesions at targeted VT site(s). Acute procedural success was defined as noninducibility of the clinical VT after the procedure. Patients underwent follow-up at 30 days, and 3 and 6 months, with implantable cardioverter defibrillator interrogation at follow-up to determine VT recurrence. Results: These refractory VT patients (91% male, 66±10 years, ejection fraction 35±11%; 56% ischemic, and 44% nonischemic) had a median of 45 device therapies (shock/antitachycardia pacing) for VT in the 3 to 6 months pre-SERF ablation. The study catheter was used to deliver an average of 10±5 lesions per case, with an average of 430±295 seconds of radiofrequency time, 122±65 minute of catheter use time, and a procedural duration of 4.3±1.3 hours. Acute procedural success was 97% for eliminating the clinical VT. At average follow-up of 5 months (n=32), device therapies were reduced by 89%. Complications included 2 periprocedural deaths: an embolic mesenteric infarct and cardiogenic shock, 2 mild strokes, and a pericardial effusion treated with pericardiocentesis (n=1). Conclusions: Intramural heated saline needle ablation showed complete acute and satisfactory mid-term control of difficult VTs failing 1 to 5 prior ablations and drug therapy. Further study is warranted to define safety and longer-term efficacy. Registration: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT03628534 and NCT02994446.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. The Current Landscape of Ventricular Tachycardia Trials: A Systematic Review of Registered Studies;Heart, Lung and Circulation;2024-08

2. Biophysics of Radiofrequency Ablation for Cardiac Arrhythmias: A Current Review;Current Treatment Options in Cardiovascular Medicine;2024-07-05

3. Ventricular Tachycardia Ablation Endpoints;JACC: Clinical Electrophysiology;2024-05

4. Ventricular Intramyocardial Navigation for Tachycardia Ablation Guided by Electrograms (VINTAGE);JACC: Clinical Electrophysiology;2024-05

5. The VINTAGE Approach;JACC: Clinical Electrophysiology;2024-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3